| Abstrakt: |
The unpredictable nature of bleeding and complications, and the highly variable nature of haemophilia A, necessitate that each patient be dealt with on an individual basis with treatment tailored to specific needs. Safety of treatment is paramount and, due to concerns over viral safety, the use of recombinant factor VIII products has increased across Europe. Prophylaxis treatment has also increased, as recent studies have shown reductions in number of joint bleeds, fewer days lost from work, less need for surgery and fewer emergency hospital visits compared with on-demand regimens. Other factors that need to be considered include convenience for the patient, consistency of supply and cost. Consequently, management of haemophilia involves complex interrelationships between the patient, family and healthcare team. [ABSTRACT FROM AUTHOR] |
